Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor-engineered T cell therapy for solid tumors

Shrikanta Chattopadhyay, Antoine Boudot, Ribhu Nayar, Hannah Bader, Tary Traore, Nancy Nabilsi, Jenny Tadros, Badr Kiaf, Yifan Wang, Victor Ospina, Alok Das Mohapatra, Zhonghua Zhu, Qikai Xu, Krista Daniels, Briana Zimmerman, Mollie Jurewicz, Amanda Kordosky, Chris Malcuit, Yun Wang, Marlyane Motta, Nina Abelowitz, Jim Murray, Ray Lockard, Cagan Gurer, Debora Barton, Gavin MacBeath **TScan Therapeutics, Waltham, MA**



- of sufficient endogenous anti-tumor T cells
- T cell receptors (TCRs) that target tumor antigens
- heterogenous target antigen expression
- HLA loss of heterozygosity (LOH) in up to 40% of tumors
- response (3-4 months)
- targeting different antigens on different HLA types
- potent tumor killing and long-term persistence.



HLA loss of heterozygosity (LOH) is prevalent and overlooked in solid tumors



and ~10-fold higher T-cell expansion in the presence of TGF β in vitro and durable responses of tumors in vivo.

Screening protocol pre-identifies patients eligible for treatment protocol

tumor patients eligible for singleplexed therapy (dotted lines) or multiplexed therapy (solid lines) increases.





#2554